Scholarlink

Purpose <p>Menopause has been associated with metabolic dysfunction-associated steatotic liver disease (MASLD). This study primarily aimed to evaluate changes in non-invasive indices of hepatic steatosis in premenopausal women with endometriosis after treatment with goserelin, resulting in pharmacologic menopause.</p> Methods <p>This was a <i>post-hoc</i> study of an interventional study. Non-invasive indices of hepatic steatosis and, secondarily, fibrosis were calculated in premenopausal women with endometriosis (intervention group, <i>n</i> = 21) before (baseline), 6 months after goserelin treatment (estrogen-deficient period), and 6 months after goserelin discontinuation (estrogen replenishment period). Matched premenopausal women were recruited for baseline comparisons (control group, <i>n</i> = 27). Steatosis was evaluated using the Hepatic Steatosis Index (HSI), Triglyceride/Glucose Index (TyG), TyG-Body Mass Index (BMI), Triglyceride/High Density Lipoprotein (TG/HDL), Metabolic Score for Insulin Resistance (MetS-IR), Dallas Steatosis Index (DSI), and Framingham Steatosis Index (FSI), and fibrosis with BMI – Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) Ratio Diabetes Mellitus (BARD).</p> Results <p>The non-invasive indices of hepatic steatosis and BARD were similar between patients and controls at baseline and did not significantly change after goserelin treatment, except for MetS-IR, which showed an overall significant change (<i>p</i> = 0.04); however, in pairwise comparisons after Bonferroni correction, no significant difference in MetS-IR was observed between baseline (34.8 ± 7.7), 6 months (33.3 ± 9.0), and endpoint (35.0 ± 8.1) values. As expected, the lipid profiles and insulin resistance worsened during the study.</p> Conclusion <p>Non-invasive hepatic steatosis and BARD indices were not significantly affected by estrogen deficiency caused by 6-month goserelin treatment in premenopausal women with endometriosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis

  • 期刊论文

  • 发表日期：

    2025年12月29日

查看全文
  • Dimitrios A. Anastasilakis,
  • Athanasios D. Anastasilakis,
  • Athina Gkiomisi,
  • Anastasios Semertzidis,
  • Panagiotis Nikolakopoulos,
  • Stergios Papachatzopoulos,
  • Angelos Daniilidis,
  • Dimitrios G. Goulis,
  • Antonis Goulas,
  • Stergios A. Polyzos

摘要

Purpose

Menopause has been associated with metabolic dysfunction-associated steatotic liver disease (MASLD). This study primarily aimed to evaluate changes in non-invasive indices of hepatic steatosis in premenopausal women with endometriosis after treatment with goserelin, resulting in pharmacologic menopause.

Methods

This was a post-hoc study of an interventional study. Non-invasive indices of hepatic steatosis and, secondarily, fibrosis were calculated in premenopausal women with endometriosis (intervention group, n = 21) before (baseline), 6 months after goserelin treatment (estrogen-deficient period), and 6 months after goserelin discontinuation (estrogen replenishment period). Matched premenopausal women were recruited for baseline comparisons (control group, n = 27). Steatosis was evaluated using the Hepatic Steatosis Index (HSI), Triglyceride/Glucose Index (TyG), TyG-Body Mass Index (BMI), Triglyceride/High Density Lipoprotein (TG/HDL), Metabolic Score for Insulin Resistance (MetS-IR), Dallas Steatosis Index (DSI), and Framingham Steatosis Index (FSI), and fibrosis with BMI – Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) Ratio Diabetes Mellitus (BARD).

Results

The non-invasive indices of hepatic steatosis and BARD were similar between patients and controls at baseline and did not significantly change after goserelin treatment, except for MetS-IR, which showed an overall significant change (p = 0.04); however, in pairwise comparisons after Bonferroni correction, no significant difference in MetS-IR was observed between baseline (34.8 ± 7.7), 6 months (33.3 ± 9.0), and endpoint (35.0 ± 8.1) values. As expected, the lipid profiles and insulin resistance worsened during the study.

Conclusion

Non-invasive hepatic steatosis and BARD indices were not significantly affected by estrogen deficiency caused by 6-month goserelin treatment in premenopausal women with endometriosis.